24 HR topiramate 100 MG Extended Release Oral Capsule
1 INDICATIONS AND USAGE Topiramate extended-release capsules are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome (LGS) in patients 6 years of age and older ( 1.2 ) Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ) 1.1 Monotherapy Epilepsy Topiramate extended-release capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older [see Clinical Studies ( 14.2 )] . 1.2 Adjunctive Therapy Epilepsy Topiramate extended-release capsules are indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 6 years of age and older [see Clinical Studies ( 14.3 )] . 1.3 Migraine Topiramate extended-release capsules are indicated for the preventive treatment of in patients 12 years of age and older [see Clinical Studies ( 14.4 )].
Zydus Pharmaceuticals (USA) Inc.
CAPSULE WHITE 769
Related Pills
24 HR topiramate 50 MG Extended Release Oral Capsule
Zydus Pharmaceuticals (USA) Inc.
24 HR topiramate 25 MG Extended Release Oral Capsule
Zydus Pharmaceuticals (USA) Inc.
dexamethasone tablet dexamethasone intensol solution concentrate dexamethasone solution
west-ward pharmaceuticals corp.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied
TOPIRAMATE Extended-Release capsules
TOPIRAMATE Extended-Release capsules are available in the following strengths: 25 mg capsules : Off white pellets filled in size '2' hard gelatin capsules with white opaque cap printed with '863' in black ink and a white opaque body and are supplied as follows: NDC 68382-863-06 in bottle of 30 capsules with child-resistant closure NDC 68382-863-16 in bottle of 90 capsules with child-resistant closure NDC 68382-863-01 in bottle of 100 capsules with child-resistant closure NDC 68382-863-05 in bottle of 500 capsules NDC 68382-863-77 in cartons of 100 (10 x 10) unit-dose capsules 50 mg capsules : Off white pellets filled in size '0' hard gelatin capsules with white opaque cap printed with '864' in black ink and a white opaque body and are supplied as follows: NDC 68382-864-06 in bottle of 30 capsules with child-resistant closure NDC 68382-864-16 in bottle of 90 capsules with child-resistant closure NDC 68382-864-01 in bottle of 100 capsules with child-resistant closure NDC 68382-864-05 in bottle of 500 capsules NDC 68382-864-77 in cartons of 100 (10 x 10) unit-dose capsules 100 mg capsules : Off white pellets filled in size '0el' hard gelatin capsules with white opaque cap printed with '769' in black ink and a white opaque body and are supplied as follows: NDC 68382-769-06 in bottle of 30 capsules with child-resistant closure NDC 68382-769-16 in bottle of 90 capsules with child-resistant closure NDC 68382-769-01 in bottle of 100 capsules with child-resistant closure NDC 68382-769-05 in bottle of 500 capsules NDC 68382-769-77 in cartons of 100 (10 x 10) unit-dose capsules 200 mg capsules: white to off-white pellets filled in size '00' hard gelatin capsules with white opaque cap printed with '358' in black ink and a white opaque body and are supplied as follows: NDC 68382-358-06 in bottle of 30 capsules with child-resistant closure NDC 68382-358-01 in bottle of 100 capsules with child-resistant closure NDC 68382-358-05 in bottle of 500 capsules NDC 68382-358-78 in cartons of 30 capsules (3 x 10 unit-dose) (Unit-dose blisters are child-resistant) 16.2 Storage and Handling
TOPIRAMATE extended-release capsules should be stored in well-closed containers at 20° to 25°C (68° to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture and light.
More pills like CAPSULE 769